Welcome back,

Tag : BCR::ABL1

CONFERENCE UPDATE

Phase 3 PhALLON trial reveals high rates of MRD negativity at any time and prolonged PFS with ponatinib in patients with newly diagnosed Ph+ ALL
Ponatinib is a third-generation BCR::ABL tyrosine kinase inhibitor (TKI) that inhibits BCR::ABL1 regardless of any single resistance mutations, including T315I.